Utility of Autologous and Allogeneic Cell Therapy for Peripheral Arterial Disease

自体和同种异体细胞疗法在外周动脉疾病中的应用

基本信息

项目摘要

DESCRIPTION (provided by applicant): The Indiana Regional Cardiovascular Cell Therapy Center (IRCCTC) will extend the work of the Cardiovascular Cell Therapy Research Network, particularly in the area of peripheral arterial disease (PAD). Critical limb ischemia (CLI) results in at least 50,000 amputations annually, with a cost estimated at $4.3 billion/year. In a recent Phase l/ll trial we have demonstrated safety and feasibility of intra-muscular injection of autologous bone marrow mononuclear cells (ABMNC) in patients with CLI, and provided initial evidence that this treatment improves amputation-free survival at one year. Although these results are promising, there is an opportunity to improve the effectiveness of cell therapy for CLI by identifying more potent sources of progenitor cells and by evaluating functional characteristics of transplanted cells. While many cardiovascular cell-based trials have focused on ABMNC, adipose stromal cells (ASCs) have demonstrated qualities particularly suitable for promoting limb salvage in CLI. In addition, cord blood mononuclear cells (CBMNC) have been shown to include vasculogenic endothelial progenitor cells, to augment perfusion in ischemic limbs, and to be tolerated by an immunocompetent host. CLI presents an excellent opportunity to examine these two readily accessible cell populations with regard to suitability for cardiovascular cell therapy, in that there exist no other options fo salvage of the index limb, potential adverse events are not immediately life-threatening, and tissue can be obtained for analysis in the event of amputation. Also, mechanisms promoting limb salvage in CLI have relevance to myocardial ischemic syndromes. In this application for a new Regional Center, we propose two protocols, respectively evaluating allogeneic cord blood mononuclear cells and adipose stromal cells as potential therapies for CLI. Aim 1 will evaluate whether CBMNC are superior to placebo in promoting amputation-free survival at 1 year in subjects with critical limb ischemia of Rutherford Category 4, and no /high-risk options for standard revascularization. Aim 2 will test the hypothesis that adipose stromal cells (ASCs) are safe and may increase time to amputation in subjects with critical limb ischemia and ulcers / tissue loss (Rutherford Category 5-6).
描述(由申请人提供): 印第安纳州地区心血管细胞治疗中心(IRCCTC)将扩展心血管细胞治疗研究网络的工作,特别是在外周动脉疾病(PAD)领域。严重肢体缺血(CLI)每年导致至少50,000例截肢,估计每年的成本为43亿美元。在最近的I/II期试验中,我们已经证明了安全性, 肌内注射自体骨髓单个核细胞(ABMNC)治疗CLI患者的可行性,并提供了初步证据表明这种治疗可提高1年无截肢生存率。虽然这些结果是有希望的,但有机会通过鉴定更有效的祖细胞来源和评估移植细胞的功能特征来提高CLI细胞治疗的有效性。虽然许多基于心血管细胞的试验都集中在ABMNC上,但脂肪基质细胞(ASCs)已经证明了特别适合在CLI中促进保肢的品质。此外,脐带血单核细胞(CBMNC)已被证明包含血管生成内皮祖细胞,可以增加缺血肢体的灌注,并且可以被免疫活性宿主耐受。CLI提供了一个极好的机会来检查这两个容易获得的细胞群是否适合心血管细胞治疗,因为没有其他选择来挽救索引肢体,潜在的不良事件不会立即危及生命,并且在截肢的情况下可以获得组织用于分析。另外,CLI中促进保肢的机制与心肌缺血综合征相关。在这个新的区域中心的申请中,我们提出了两个方案,分别评估同种异体脐带血单核细胞和脂肪基质细胞作为CLI的潜在疗法。目的1将评价CBMNC在促进Rutherford 4类严重肢体缺血受试者1年无截肢生存率方面是否上级安慰剂,并且标准血运重建无/高风险选择。目的2将检验以下假设:脂肪基质细胞(ASC)是安全的,可能会延长严重肢体缺血和溃疡/组织缺损受试者的截肢时间(Rutherford分类5-6)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KEITH LEONARD MARCH其他文献

KEITH LEONARD MARCH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KEITH LEONARD MARCH', 18)}}的其他基金

Functional and Mechanistic Analysis of Mesenchymal Stem Cell Secretome to Ameliorate Ischemic Damage of Rodent Hearts in situ and Human Myocardium-on-a-Chip
间充质干细胞分泌组改善啮齿动物原位心脏和人心肌芯片缺血损伤的功能和机制分析
  • 批准号:
    9898148
  • 财政年份:
    2017
  • 资助金额:
    $ 20.68万
  • 项目类别:
Functional and Mechanistic Analysis of Mesenchymal Stem Cell Secretome to Ameliorate Ischemic Damage of Rodent Hearts in situ and Human Myocardium-on-a-Chip
间充质干细胞分泌组改善啮齿动物原位心脏和人心肌芯片缺血损伤的功能和机制分析
  • 批准号:
    10394875
  • 财政年份:
    2017
  • 资助金额:
    $ 20.68万
  • 项目类别:
Functional and Mechanistic Analysis of Mesenchymal Stem Cell Secretome to Ameliorate Ischemic Damage of Rodent Hearts in situ and Human Myocardium-on-a-Chip
间充质干细胞分泌组改善啮齿动物原位心脏和人心肌芯片缺血损伤的功能和机制分析
  • 批准号:
    9352535
  • 财政年份:
    2017
  • 资助金额:
    $ 20.68万
  • 项目类别:
Functional and Mechanistic Analysis of Mesenchymal Stem Cell Secretome to Ameliorate Ischemic Damage of Rodent Hearts in situ and Human Myocardium-on-a-Chip
间充质干细胞分泌组改善啮齿动物原位心脏和人心肌芯片缺血损伤的功能和机制分析
  • 批准号:
    10265387
  • 财政年份:
    2017
  • 资助金额:
    $ 20.68万
  • 项目类别:
Utility of Autologous and Allogeneic Cell Therapy for Peripheral Arterial Disease
自体和同种异体细胞疗法在外周动脉疾病中的应用
  • 批准号:
    9039127
  • 财政年份:
    2012
  • 资助金额:
    $ 20.68万
  • 项目类别:
Utility of Autologous and Allogeneic Cell Therapy for Peripheral Arterial Disease
自体和同种异体细胞疗法在外周动脉疾病中的应用
  • 批准号:
    8622215
  • 财政年份:
    2012
  • 资助金额:
    $ 20.68万
  • 项目类别:
Utility of Autologous and Allogeneic Cell Therapy for Peripheral Arterial Disease
自体和同种异体细胞疗法在外周动脉疾病中的应用
  • 批准号:
    8443414
  • 财政年份:
    2012
  • 资助金额:
    $ 20.68万
  • 项目类别:
Utility of Autologous and Allogeneic Cell Therapy for Peripheral Arterial Disease
自体和同种异体细胞疗法在外周动脉疾病中的应用
  • 批准号:
    8288419
  • 财政年份:
    2012
  • 资助金额:
    $ 20.68万
  • 项目类别:
Direct and Bone-Marrow Mediated Effects of Adipose Stem Cells in Emphysema
脂肪干细胞对肺气肿的直接作用和骨髓介导作用
  • 批准号:
    8802885
  • 财政年份:
    2011
  • 资助金额:
    $ 20.68万
  • 项目类别:
Direct and Bone-Marrow Mediated Effects of Adipose Stem Cells in Emphysema
脂肪干细胞对肺气肿的直接作用和骨髓介导作用
  • 批准号:
    8392234
  • 财政年份:
    2011
  • 资助金额:
    $ 20.68万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.68万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了